Evidence map›Paper›PMID 29874375›Full record

Trial reportJAMA surgery2018

Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.

Julia Kitz, Emmanouil Fokas, Tim Beissbarth, Philipp Ströbel, Christian Wittekind, Arndt Hartmann, Josef Rüschoff, Thomas Papadopoulos, Elisabeth Rösler, Peter Ortloff-Kittredge and 13 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 7 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00349076 phase3completednot on this map

Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rectal Cancer

TypeinterventionalSponsorUniversity of Erlangen-Nürnberg Medical SchoolRan2006 to 2016Enrolled1,256ConditionsRectal NeoplasmsArms5-FU and oxaliplatin, 5-FU
NCT07138859 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Prospective, Multiceter, Randomized, Controlled Study on the Intraoperative Technical Errors of Robotic vs. Laparoscopic Radical Right Hemiclectomy (Superiority Design,ROBOGEON® 2501study)

TypeinterventionalSponsorThe Affiliated Hospital of Qingdao UniversityRan2025 to 2030Enrolled368ConditionsColorectal Carcinoma (CRC), Right HemicolectomyArmsRobot assisted radical right hemicolectomy (D3 lymph node dissection), Laparoscopic assisted radical right hemicolectomy (D3 lymph node dissection)
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 7 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Three-dimensionalIn vivo (Athens, Greece)
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Simultaneous integrated boost to lateral pelvic lymph nodes during chemoradiotherapy in high-risk rectal cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 1 country.

Julia KitzInstitute of Pathology, University Medical Center Göttingen, Göttingen, Germany.
Emmanouil FokasDepartment of Radiotherapy and Oncology, University of Frankfurt, Frankfurt, Germany.
Tim BeissbarthDepartment of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
Philipp StröbelInstitute of Pathology, University Medical Center Göttingen, Göttingen, Germany.
Christian WittekindInstitute of Pathology, University Medical Center Leipzig, Leipzig, Germany.
Arndt HartmannInstitute of Pathology, University Medical Center Erlangen, Erlangen, Germany.
Josef RüschoffInstitute of Pathology Nordhessen, Kassel, Germany.
Thomas PapadopoulosInstitute of Pathology, Klinikum Nürnberg Nord, Nuremberg, Germany.
Elisabeth RöslerInstitute of Pathology, Mönchengladbach, Germany.
Peter Ortloff-KittredgeInstitute of Pathology, Mönchengladbach, Germany.
Ulrich KaniaDepartment of General and Visceral Surgery, Krankenhaus Maria Hilf, Mönchengladbach, Germany.
Hans SchlittDepartment of Visceral Surgery, University Medical Center Regensburg, Regensburg, Germany.
Karl-Heinrich LinkDepartment of Visceral Surgery, Asklepios Paulinen Klinik Wiesbaden, Wiesbaden, Germany.
Wolf BechsteinDepartment of General and Visceral Surgery, University Medical Center Frankfurt, Frankfurt, Germany.
Hans-Rudolf RaabDepartment of General and Visceral Surgery, University Medical Center Oldenburg, Oldenburg, Germany.
Ludger StaibDepartment of General and Visceral Surgery, Klinikum Esslingen, Esslingen, Germany.
Christoph-Thomas GermerDepartment of General, Visceral, Vascular and Pediatric Surgery, University Hospital Würzburg, Würzburg, Germany.
Torsten LierschDepartment of General and Visceral Surgery, University Medical Center Göttingen, Göttingen, Germany.
Rolf SauerDepartment of Radiation Therapy, University of Erlangen, Erlangen, Germany.
Claus RödelDepartment of Radiotherapy and Oncology, University of Frankfurt, Frankfurt, Germany.
Michael GhadimiDepartment of General and Visceral Surgery, University Medical Center Göttingen, Göttingen, Germany.
Werner HohenbergerDepartment of General and Visceral Surgery, University of Erlangen, Erlangen, Germany.
German Rectal Cancer Study Group
Universitätsmedizin Göttingen · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGoethe University Frankfurt · DEStädtische Kliniken Mönchengladbach · DEAsklepios Fachklinikum Brandenburg · DEKliniken Maria Hilf · DEKlinikum Esslingen · DEKlinikum Oldenburg · DELeipzig University · DENuremberg Hospital · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Previous retrospective studies have shown that surgical quality affects local control in rectal cancer.. Objective: In this secondary end point analysis, we evaluated the prognostic effect of the total mesorectal excision (TME) plane in the CAO/ARO/AIO-04 phase 3 randomized clinical trial. Design, Setting, and Participants: The CAO/ARO/AIO-04 trial enrolled 1236 patients with cT3-4 and/or node-positive rectal adenocarcinoma from 88 centers in Germany between July 25, 2006, and February 26, 2010. Interventions: Patients were randomized to receive treatment with standard fluorouracil-based preoperative chemoradiotherapy (CRT) alone (control arm) or oxaliplatin (experimental arm) followed by TME and adjuvant chemotherapy. Main Outcomes and Measures: The TME quality (mesorectal, intramesorectal, and muscularis propria plane) was prospectively assessed in 1152 operation specimens. An assessment was performed independently by pathologists and surgeons. The results were correlated with clinicopathologic data and the clinical outcome was tested, including multivariable analysis with the Cox regression model. Results: Of 1152 German Caucasian participants, 332 (28.8) were women and the mean age was 63 years. The plane of TME was mesorectal in 930 patients (80.7%), intramesorectal in 169 (14.7%), and muscularis propria in 53 (4.6%). In a univariable analysis, the TME plane was significantly associated with 3-year disease-free survival (mesorectal vs intramesorectal vs muscularis propria, 95% CI, 73.1-78.8 vs 61.6-76.0 vs 55.6-81.3, respectively; P = .01), cumulative incidence of local and distant recurrences (mesorectal vs intramesorectal vs muscularis propria, 95% CI, 2.0-4.5 vs 1.2-8.1 vs 2.5-20.5, respectively; P < .001; and mesorectal vs intramesorectal vs muscularis propria, 95% CI, 17.0-22.4 vs 18.3-32.0 vs 14.2-39.0, respectively; P = .03, respectively), and overall survival (mesorectal vs intramesorectal vs muscularis propria, 95% CI, 88.3-92.3 vs 79.7-91.0 vs 81.6-98.7, respectively; P = .02). In contrast to the pathologist-based evaluation, the assessment of TME plane by the operating surgeon failed to demonstrate prognostic significance for any of these clinical end points. In a multivariable analysis, the plane of surgery (mesorectal vs muscularis propria TME) constituted an independent factor for local recurrence (P = .002). Conclusions and Relevance: This phase 3 randomized clinical trial confirms the long-term clinical effect of TME plane quality on local recurrence, as initially reported in the MRC CR07 study. The data highlight the key role of pathologists and surgeons in the multidisciplinary management of rectal cancer. Trial Registration: ClinicalTrials.gov Identifier: NCT00349076.

Indexed as

Neoplasm StagingAdenocarcinomaChemoradiotherapyDigestive System Surgical ProceduresDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm MetastasisPrognosisRectal NeoplasmsRectumRetrospective Studies

Identifiers

PMID29874375
PMCPMC6142959
OpenAlexW2805908456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.